Erleada (apalutamide) was recently approved for non-metastatic CRPC.
/www.jnj.com/media-center/press-releases/erleada-apalutamide-a-next-generation-androgen-receptor-inhibitor-granted-us-fda-approval-for-the-treatment-of-patients-with-non-metastatic-castration-resistant-prostate-cancer(If/when you may become metastatic, chemo with Docetaxel or Zytiga plus prednisone may be options, too. Or possibly Provenge, or possibly other immune combinations in Clinical Trials.)
Ask you doctor. Consider getting a second opinion from a prostate cancer expert at a regional center of excellence, if you have not already done so.
Just some thoughts...
Charles